// App-Quantinova.ai

3501 : Nivolumab ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.

Researchers

Presenter

  • Michael J. Overman

Principal Investigators

  • Scott Kopetz

  • Raymond S. McDermott

  • Joseph Leach

  • Sara Lonardi

  • Heinz-Josef Lenz

  • Michael A. Morse

  • Jayesh Desai

  • Andrew Hill

  • Michael D. Axelson

  • Rebecca Anne Moss

  • Chen-Sheng Lin

  • Monica Goldberg

  • Thierry Andre

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • St Vincent's University Hospital, Dublin, Ireland

  • Allina Health, Minneapolis, MN

  • Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy

  • University of Southern California, Los Angeles, CA

  • Duke University Office of Research Administration, Durham, NC

  • Royal Melbourne Hospital, Melbourne, Australia

  • Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Hospital Saint Antoine, Paris, France

Locations

  • Ireland

  • Italy

  • Australia

  • United States

  • France

Companies

  • Tasman Oncology Rese

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved